Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Median 25(OH)D levels at T1 were 139.9 (interquartile range 123.5 to 161.2) and 74.5 nmol/L (58.6 to 88.1) in the vitamin D3 and placebo group, respectively (p < 0.001).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Double-blind reported · Human research reported

Reported blinded roles: participants.

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This was a multi-center, double-blind, placebo-controlled supplementation study.

Source: Methods.

The study was initially designed as a randomized controlled clinical trial to measure the effects of vitamin D3 supplements on primary outcome area under the curve (AUC) of cortisol day curves (CDC) in RRMS patients in the context of depressive complaints.

Source: Methods.

All participants were female patients with RRMS, according to the McDonald criteria ().

Source: Methods.

Study personnel, participants, and care providers were blinded to the study interventions.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis

Randomised controlled trial · Frontiers in Neurology · 2018

Original publication title

Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis

Linda Rolf; Jan Damoiseaux; Inge Huitinga; Dorien Kimenai; Jody van den Ouweland; Raymond Hupperts; Joost Smolders

Copyright © 2018 Rolf, Damoiseaux, Huitinga, Kimenai, van den Ouweland, Hupperts and Smolders.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Suppression of HPA-axis activity by vitamin D3 supplements in non-depressed MS patients may be best reflected by CAR as primary outcome measure. Further studies should address this interaction and its potential implications for the disease course of MS.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Multiple sclerosis (MS) has been associated with both a poor vitamin D status and hyperactivity of the hypothalamus: pituitary: adrenal (HPA) axis. Since nuclear receptor ligands may regulate each other, we explored the association of vitamin D3 supplements with circadian cortisol levels in a double-blind and placebo-controlled supplementation study.

Source: Introduction

Abstract: What methods does the paper describe?

Female patients with relapsing-remitting MS received vitamin D3 supplements (4,000 IU/day; n = 22) or placebo (n = 19) during 16 weeks. Salivary cortisol levels, repeatedly measured during the day, and serum 25(OH)D levels were assessed before (T0) and after (T1) this treatment period.

Source: Methods

Abstract: Registration

This study was registered on ClinicalTrials.gov (NCT02096133) and EudraCT (2014-000728-97).

Source: Registration

Abstract: Results

Median 25(OH)D levels at T1 were 139.9 (interquartile range 123.5 to 161.2) and 74.5 nmol/L (58.6 to 88.1) in the vitamin D3 and placebo group, respectively (p < 0.001). Comparisons within and between groups showed no differences in area under the curve (AUC) and slope of the cortisol day curve. Although the AUC of the cortisol awakening response (CAR, sampling each 15 min the first hour after awakening) showed a reduction over time in the vitamin D3 group [39.16 nmol/L (27.41 to 42.07) at T0 to 33.37 nmol/L (26.75 to 38.08) at T1] compared to the placebo group [33.90 nmol/L (25.92 to 44.61) at T0 to 35.00 nmol/L (25.46 to 49.23) at T1; p = 0.044], there was no significant difference in AUC of CAR at T1 corrected for baseline AUC of CAR (p = 0.066).

Source: Results

Abstract: Conclusion

Suppression of HPA-axis activity by vitamin D3 supplements in non-depressed MS patients may be best reflected by CAR as primary outcome measure. Further studies should address this interaction and its potential implications for the disease course of MS.

Source: Conclusion
Authors’ abstract

Introduction

Multiple sclerosis (MS) has been associated with both a poor vitamin D status and hyperactivity of the hypothalamus: pituitary: adrenal (HPA) axis. Since nuclear receptor ligands may regulate each other, we explored the association of vitamin D3 supplements with circadian cortisol levels in a double-blind and placebo-controlled supplementation study.

Methods

Female patients with relapsing-remitting MS received vitamin D3 supplements (4,000 IU/day; n = 22) or placebo (n = 19) during 16 weeks. Salivary cortisol levels, repeatedly measured during the day, and serum 25(OH)D levels were assessed before (T0) and after (T1) this treatment period.

Results

Median 25(OH)D levels at T1 were 139.9 (interquartile range 123.5 to 161.2) and 74.5 nmol/L (58.6 to 88.1) in the vitamin D3 and placebo group, respectively (p < 0.001). Comparisons within and between groups showed no differences in area under the curve (AUC) and slope of the cortisol day curve. Although the AUC of the cortisol awakening response (CAR, sampling each 15 min the first hour after awakening) showed a reduction over time in the vitamin D3 group [39.16 nmol/L (27.41 to 42.07) at T0 to 33.37 nmol/L (26.75 to 38.08) at T1] compared to the placebo group [33.90 nmol/L (25.92 to 44.61) at T0 to 35.00 nmol/L (25.46 to 49.23) at T1; p = 0.044], there was no significant difference in AUC of CAR at T1 corrected for baseline AUC of CAR (p = 0.066).

Conclusion

Suppression of HPA-axis activity by vitamin D3 supplements in non-depressed MS patients may be best reflected by CAR as primary outcome measure. Further studies should address this interaction and its potential implications for the disease course of MS.

Registration

This study was registered on ClinicalTrials.gov (NCT02096133) and EudraCT (2014-000728-97).

Publication and source details

Original title: Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis

Linda Rolf; Jan Damoiseaux; Inge Huitinga; Dorien Kimenai; Jody van den Ouweland; Raymond Hupperts; Joost Smolders

Frontiers in Neurology · 2018

Edited by: Zsolt Illes, University of Southern Denmark Odense, Denmark

Reviewed by: Anthony T. Reder, University of Chicago, United States; Pavan Bhargava, Johns Hopkins University, United States

*Correspondence: Joost Smolders, j.smolders@cwz.nl

Specialty section: This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology

Copyright © 2018 Rolf, Damoiseaux, Huitinga, Kimenai, van den Ouweland, Hupperts and Smolders.2018Rolf, Damoiseaux, Huitinga, Kimenai, van den Ouweland, Hupperts and Smoldershttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Nationaal MS fonds NederlandMerck KGaA10.13039/100009945

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T13:20:06.251823+00:00

DOI: 10.3389/fneur.2018.00263 · PMC5933207